AffiliationDepartment of Surgery, Northern General Hospital, Sheffield, England.
MetadataShow full item record
AbstractHypercalcemia is the most common paraneoplastic syndrome associated with cancer. This paper addresses the etiology and pathogenesis of hypercalcemia of malignancy and discusses the relative contributions of local and humoral effects on bone and renal calcium homeostasis. The roles of parathyroid hormone-related protein and other osteolytic cytokines are outlined. New biochemical markers that enable more specific monitoring of the response of bone metastases to treatment are introduced, including urinary excretion of the collagen crosslinks pyridinoline and deoxypyridinoline. The clinical management and prevention of hypercalcemia is systemically outlined, including indications for bisphosphonate, glucocorticoid, and calcitonin therapy. The results of recent trials of bisphosphonate therapy for the prevention of tumor progression and its subsequent problems such as bone pain, fracture, and hypercalcemia also are discussed.
CitationHypercalcemia and bone resorption in malignancy. 1995 (312):51-63 Clin. Orthop. Relat. Res.
JournalClinical Orthopaedics and Related Research
- Role of parathyroid hormone-related peptide in hypercalcemia of malignancy and the development of osteolytic metastases.
- Authors: de Vernejoul MC
- Issue date: 1997 Jun 30
- Mechanisms of cancer-induced hypercalcemia.
- Authors: Rosol TJ, Capen CC
- Issue date: 1992 Dec
- Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone.
- Authors: Clines GA, Guise TA
- Issue date: 2005 Sep
- Hypercalcemia of malignancy: the central role of parathyroid hormone-related protein.
- Authors: Wysolmerski JJ, Broadus AE
- Issue date: 1994
- Bisphosphonates for cancer patients: why, how, and when?
- Authors: Body JJ, Mancini I
- Issue date: 2002 Jul